Evidence map›Paper›PMID 33509219›Full record

ArticleOrphanet journal of rare diseases2021

I Gallais Sérézal, S Ferkal, L Lerman, S Mulé, B Funalot, P Wolkenstein

Open access · goldAbstract readLetter
In one paragraph

Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

I Gallais SérézalService de Dermatologie, Centre Hospitalo-Universitaire de Besançon, Besançon, France.ORCID 0000-0002-7301-9699
S FerkalINSERM, Centre D'Investigation Clinique 006, centre de référence des neurofibromatoses, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France.
L LermanService de Médecine Nucléaire, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France.
S MuléService de Radiologie, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France.
B FunalotDépartement de Génétique, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France.
P WolkensteinINSERM, Centre D'Investigation Clinique 006, centre de référence des neurofibromatoses, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France. pierre.wolkenstein@aphp.fr.
Assistance Publique – Hôpitaux de Paris · FRInserm · FRCentre Hospitalier Universitaire de Besançon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schwannomatosis is a rare autosomal dominant genetic syndrome characterized by the presence of multiple schwannomas. The main symptom is neurogenic pain. The diagnosis requires the presence of several schwannomas and whole-body

Indexed as

Fluorodeoxyglucose F18NeurilemmomaFemaleHumansMagnetic Resonance ImagingMaleNeurofibromatosesPositron-Emission TomographySensitivity and SpecificitySkin NeoplasmsWhole Body ImagingFluorodeoxyglucose F18[18F]FDG-PETDiagnosisMRISchwannomatosis

Identifiers

PMID33509219
PMCPMC7842033
OpenAlexW3124774042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.